Skip to content
Artwork for Flot.bio x Philip Hemme
Flot.bio x Philip Hemme · Nov 17, 2025 · 53 min

Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis, Inflammation | E46

When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes. Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround. Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team. ⭐️ ABOUT THE SPEAKER Marc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech companies through billion-dollar exits (CinCor Pharma and Corvidia Therapeutics). He also served as CEO of Ipsen from 2010 to 2016, and has worked at the likes of Amgen and Eli Lilly. 🔗 LINKS MENTIONED Abivax’s website - https://www.abivax.com/ Phase 3 results - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week $747.5 million public offering - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-closing-7475-million-public-offering Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09 - https://flot.bio/episode/marc-de-garidel-abivax-exit/ Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34 - https://flot.bio/episode/chris-martin-verona-pharma-copd/ Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31 https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/ Nanobiotix episode - https://www.youtube.com/watch?v=3Krhyy6a-nw&pp=0gcJCQMKAYcqIYzv Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43 - https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marc-de-garidel-abivax-ulcerative-colitis-inflammation/ 📖 SHORT BLOGS BASED ON THIS EPISODE: Abivax's Record NASDAQ Stock Surge After Phase 3 Data: https://flot.bio/abivax-biotech-stock-phase-3/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmH LinkedIn: https://www.linkedin.com/company/flot-bio/ X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free. ⏰ TIMESTAMPS 0:44: Abivax’s crazy Ph3 data and stock price jump 4:06: Surging investor demand on NASDAQ and Euronext 8:58: Future directions 11:02: Executing a Phase 3 home run 17:20: Marc de Garidel's leadership style 21:58: Abivax: origins 34:51: France's billion-dollar biotechs 44:11: Quick-fire questions

0:00-53:40

transcript

No transcript — this publisher did not publish one.

show notes

When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes.

Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround.

Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team.


⭐️ ABOUT THE SPEAKER

Marc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech companies through billion-dollar exits (CinCor Pharma and Corvidia Therapeutics). He also served as CEO of Ipsen from 2010 to 2016, and has worked at the likes of Amgen and Eli Lilly.


🔗 LINKS MENTIONED


📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/marc-de-garidel-abivax-ulcerative-colitis-inflammation/


📖 SHORT BLOGS BASED ON THIS EPISODE:


💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme


⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!


🫶 FOLLOW US


🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.


🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.


⏰ TIMESTAMPS

  • 0:44: Abivax’s crazy Ph3 data and stock price jump
  • 4:06: Surging investor demand on NASDAQ and Euronext
  • 8:58: Future directions
  • 11:02: Executing a Phase 3 home run
  • 17:20: Marc de Garidel's leadership style
  • 21:58: Abivax: origins
  • 34:51: France's billion-dollar biotechs
  • 44:11: Quick-fire questions
links14